Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Use advanced search instead (articles only)
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Dermatological Diseases
Vol. 2, Issue 1, 2014
October 01, 2014 EDT
Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting
Michael Willis
,
Sandra Erntoft
,
Sofie Persson
,
Jenny M. Norlin
,
Ulf Persson
,
topical agents
contingent valuation
patient preferences
local skin reactions
actinic keratosis
willingness-to-pay
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9879
JHEOR
1.
Willis M, Erntoft S, Persson S, Norlin JM, Persson U. Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting.
JHEOR
. 2014;2(1):1-14.
doi:10.36469/9879
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats